ArticleScientific reports2025
Estimating liver cirrhosis severity with extracellular volume fraction by spectral CT.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CT-derived hepatic extracellular volume fraction for the assessment of graft rejection after liver transplantation: a retrospective observational study.Abdominal radiology (New York) · 2026Article
- LC-Pred: A Transformer-Based Interactive Interface for Liver Cirrhosis Prediction.International journal of hepatology · 2026Article
- Review
- Dual Energy CT-Derived Liver Extracellular Volume Fraction for Assessing Liver Functional Reserve in Patients with Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To investigate the diagnostic value of spectral CT in calculating extracellular volume fraction (ECV) for assessing the severity of liver cirrhosis. This retrospective study enrolled 172 participants, including 127 patients diagnosed with liver cirrhosis and 45 matched controls, all of whom underwent spectral CT hepatic enhancement imaging. Disease severity stratification was performed using the Child-Pugh classification system. ECV values were derived from the iodine density map during the delayed phase. These ECV values were then compared across the control group and subclassified cirrhosis groups (Child-Pugh classes A-C). Furthermore, a correlation analysis was performed to assess the relationship between ECV values and Child-Pugh scores in liver cirrhosis. Receiver operating characteristic (ROC) curves were constructed to evaluate the diagnostic performance of ECV values and MELD-Na in the Child-Pugh classification of liver cirrhosis. The ECV values were 25.49 ± 3.15, 29.73 ± 3.20, 35.64 ± 3.15, and 45.30 ± 5.16 for the control, Child-Pugh A, Child-Pugh B, and Child-Pugh C group, respectively, demonstrating significant intergroup differences (F = 184.67 P < 0.001). A strong positive correlation was observed between ECV and Child-Pugh liver function classification (r = 0.791, P < 0.001). The diagnostic performance of ECV for differentiating between Child-Pugh classes A and B (AUC: 0.901), B and C (AUC: 0.966) was higher compared to the MELD-Na score (AUC: 0.772 and 0.868) (P < 0.05, respectively). Multivariate analyses showed that ECV was an independent factor for cirrhosis (OR 1.610, P < 0.001). ECV values measured using spectral CT can serve as a noninvasive biomarker for assessing the severity of liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.